Technical Analysis for COCP - Cocrystal Pharma, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.70 | -2.61% | -0.05 |
Earnings due: Nov 11
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 200 DMA Resistance | Bearish | -2.61% | |
| 50 DMA Resistance | Bearish | -2.61% | |
| Calm After Storm | Range Contraction | -2.61% | |
| Oversold Stochastic | Weakness | -2.61% | |
| 20 DMA Resistance | Bearish | -5.56% | |
| Fell Below 200 DMA | Bearish | -5.56% |
| Alert | Time |
|---|---|
| Down 3% | about 10 hours ago |
| Fell Below Previous Day's Low | about 10 hours ago |
| Down 2 % | about 12 hours ago |
| Down 1% | about 12 hours ago |
| 60 Minute Opening Range Breakdown | about 12 hours ago |
Get a Trading Assistant
- Earnings date: 11/11/2024
Cocrystal Pharma, Inc. Description
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Influenza Coronavirus Viruses Microbiology Virus Antiviral Drug Biocides HCV Influenza Viruses Opko Health Pharmaceuticals Industries
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.1 |
| 52 Week Low | 1.325 |
| Average Volume | 16,543 |
| 200-Day Moving Average | 1.84 |
| 50-Day Moving Average | 1.80 |
| 20-Day Moving Average | 1.89 |
| 10-Day Moving Average | 1.80 |
| Average True Range | 0.15 |
| RSI (14) | 41.86 |
| ADX | 27.05 |
| +DI | 25.64 |
| -DI | 17.00 |
| Chandelier Exit (Long, 3 ATRs) | 1.99 |
| Chandelier Exit (Short, 3 ATRs) | 2.14 |
| Upper Bollinger Bands | 2.17 |
| Lower Bollinger Band | 1.61 |
| Percent B (%b) | 0.17 |
| BandWidth | 29.96 |
| MACD Line | -0.02 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.027 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.88 | ||||
| Resistance 3 (R3) | 1.89 | 1.85 | 1.85 | ||
| Resistance 2 (R2) | 1.85 | 1.80 | 1.84 | 1.84 | |
| Resistance 1 (R1) | 1.77 | 1.77 | 1.75 | 1.76 | 1.83 |
| Pivot Point | 1.73 | 1.73 | 1.72 | 1.72 | 1.73 |
| Support 1 (S1) | 1.65 | 1.68 | 1.63 | 1.64 | 1.57 |
| Support 2 (S2) | 1.61 | 1.65 | 1.60 | 1.56 | |
| Support 3 (S3) | 1.53 | 1.61 | 1.55 | ||
| Support 4 (S4) | 1.52 |
